These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 31801012

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tildrakizumab for the treatment of psoriasis.
    Bangert C, Kopp T.
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [Abstract] [Full Text] [Related]

  • 3. Tildrakizumab for treating psoriasis.
    Galluzzo M, D'adamio S, Bianchi L, Talamonti M.
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R.
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [Abstract] [Full Text] [Related]

  • 6. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
    Crowley JJ, Warren RB, Cather JC.
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
    [Abstract] [Full Text] [Related]

  • 7. Targeting IL-23 in psoriasis: current perspectives.
    Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D.
    Psoriasis (Auckl); 2018 Sep; 8():1-5. PubMed ID: 29441315
    [Abstract] [Full Text] [Related]

  • 8. Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis.
    Näslund-Koch C, Zachariae C, Skov L.
    Ther Clin Risk Manag; 2020 Sep; 16():903-916. PubMed ID: 33061395
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A.
    Curr Pharm Biotechnol; 2021 Sep; 22(1):7-31. PubMed ID: 32598253
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM.
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review.
    Salimi S, Yamauchi PS, Thakur R, Weinberg JM, Kircik L, Abdelmaksoud A, Wollina U, Lotti T, Sharma A, Grabbe S, Goldust M.
    Dermatol Ther; 2020 Jul; 33(4):e13800. PubMed ID: 32530083
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
    Yiu ZZ, Warren RB.
    Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis.
    Wytsma J, Woo TE, Parsons L.
    Skin Therapy Lett; 2024 May; 29(3):5-8. PubMed ID: 38781953
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.